A1 Refereed original research article in a scientific journal
Dexmedetomidin – Pharmacokinetics and pharmacodynamics
Subtitle: Pharmacokinetics and pharmacodynamics
Authors: Ihmsen H, Saari TI
Publisher: SPRINGER
Publication year: 2012
Journal: Anaesthesist
Journal name in source: ANAESTHESIST
Journal acronym: ANAESTHESIST
Volume: 61
Issue: 12
First page : 1059
Last page: 1066
Number of pages: 7
ISSN: 0003-2417
DOI: https://doi.org/10.1007/s00101-012-2114-1
Abstract
Dexmedetomidine is a highly selective, potent alpha(2)-adrenoceptor agonist which was approved in 2011 by the European Medicines Agency for sedation of patients in intensive care units (ICU). Dexmedetomidine exhibits sedative as well as analgesic and anxiolytic effects. Recent studies suggest that dexmedetomidine may be an alternative to midazolam in long-term ICU sedation. This review summarizes the pharmacokinetics and pharmacodynamics of dexmedetomidine particularly in ICU patients and with special regard to covariate effects. Although dexmedetomidine is currently approved only for use in adults the pharmacokinetics and pharmacodynamics in children will also be addressed as there are numerous studies on this off-label use.
Dexmedetomidine is a highly selective, potent alpha(2)-adrenoceptor agonist which was approved in 2011 by the European Medicines Agency for sedation of patients in intensive care units (ICU). Dexmedetomidine exhibits sedative as well as analgesic and anxiolytic effects. Recent studies suggest that dexmedetomidine may be an alternative to midazolam in long-term ICU sedation. This review summarizes the pharmacokinetics and pharmacodynamics of dexmedetomidine particularly in ICU patients and with special regard to covariate effects. Although dexmedetomidine is currently approved only for use in adults the pharmacokinetics and pharmacodynamics in children will also be addressed as there are numerous studies on this off-label use.
UTU Research Portal